| P50 | author | Hendrée E. Jones | Q65093844 |
| P2093 | author name string | Susan Hayashi | |
| | Melinda Campopiano | |
| | Anne Leopold | |
| | Stacey L Klaman | |
| | Krystyna Isaacs | |
| | Jeff Vender | |
| | Joseph Perpich | |
| P2860 | cites work | Pharmacological interventions for promoting smoking cessation during pregnancy | Q24186969 |
| | Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence | Q24239965 |
| | Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome | Q24594941 |
| | Morphine versus clonidine for neonatal abstinence syndrome | Q56768613 |
| | Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants | Q74182966 |
| | Neonatal abstinence syndrome following abrupt cessation of breastfeeding | Q74597140 |
| | Methadone maintenance and breastfeeding in the neonatal period | Q80425781 |
| | Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up | Q80727610 |
| | Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment | Q82095298 |
| | Buprenorphine and naloxone compared with methadone treatment in pregnancy | Q86493677 |
| | Neonatal abstinence syndrome | Q87458695 |
| | Cohort Analysis of a Pharmacokinetic-Modeled Methadone Weaning Optimization for Neonatal Abstinence Syndrome | Q41205581 |
| | Implementation of a Neonatal Abstinence Syndrome Weaning Protocol: A Multicenter Cohort Study | Q41359097 |
| | Opioid dependence during pregnancy. Effects and management | Q41740838 |
| | Tapering from Methadone or Buprenorphine during Pregnancy: Maternal and Neonatal Outcomes in Norway 1996-2009. | Q41743013 |
| | Dosing adjustments in postpartum patients maintained on buprenorphine or methadone | Q42730415 |
| | Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy | Q43073186 |
| | Predictors of neonatal outcomes amongst a methadone- and/or heroin-dependent population referred to a multidisciplinary Perinatal and Family Drug Health Service | Q43525411 |
| | Are infants exposed to methadone in utero at an increased risk for mortality? | Q43564125 |
| | Buprenorphine treatment of pregnant opioid--dependent women: maternal and neonatal outcomes | Q43571815 |
| | Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series | Q43813287 |
| | Improving Access to Maternity Care for Women with Opioid Use Disorders: Colocation of Midwifery Services at an Addiction Treatment Program | Q44334753 |
| | Naltrexone in the treatment of opioid-dependent pregnant women: common ground | Q44337596 |
| | Identification of early developmental deficits in infants with prenatal heroin, methadone, and other opioid exposure | Q44346925 |
| | Visual selective attention is impaired in children prenatally exposed to opioid agonist medication | Q44348181 |
| | Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes | Q44348197 |
| | Neonatal abstinence scores in opioid-exposed and nonexposed neonates: a blinded comparison | Q44349156 |
| | Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome | Q44349294 |
| | Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes | Q44756475 |
| | Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops | Q45193433 |
| | The effect of methadone dose regimen on neonatal abstinence syndrome | Q46789286 |
| | Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study | Q46918315 |
| | The relationship between maternal use of heroin and methadone and infant birth weight | Q47292996 |
| | Antenatal substance misuse and smoking and newborn hypoxic challenge response. | Q47945233 |
| | Neonatal Abstinence Syndrome: Presentation and Treatment Considerations | Q48012813 |
| | Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy | Q48578848 |
| | Does concurrent in utero exposure to buprenorphine and antidepressant medications influence the course of neonatal abstinence syndrome? | Q51012798 |
| | Rooming-In to Treat Neonatal Abstinence Syndrome: Improved Family-Centered Care at Lower Cost. | Q51326270 |
| | Intraprofessional Excellence in Nursing: Collaborative Strategies for Neonatal Abstinence Syndrome. | Q51549027 |
| | Neonatal abstinence syndrome: assessment and management | Q52264725 |
| | The effect of opiates on the activity of human placental aromatase/CYP19. | Q53696830 |
| | Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome | Q24628765 |
| | Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial | Q24647455 |
| | Substance use during pregnancy | Q26745402 |
| | Management of psychotropic drugs during pregnancy | Q26770627 |
| | Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review | Q26995853 |
| | Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child | Q28073116 |
| | ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015 | Q28081894 |
| | Opioids in pregnancy and neonatal abstinence syndrome | Q28082706 |
| | Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review | Q28083156 |
| | The role of screening, brief intervention, and referral to treatment in the perinatal period | Q30244014 |
| | Neonatal abstinence syndrome after methadone or buprenorphine exposure | Q30499416 |
| | Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data | Q30619876 |
| | How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach | Q31043972 |
| | Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis | Q33692098 |
| | Postpartum changes in methadone maintenance dose | Q33954082 |
| | Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy | Q33982854 |
| | Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes | Q34065531 |
| | Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy | Q34078458 |
| | Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates | Q34186492 |
| | Neonatal drug withdrawal | Q34250791 |
| | Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. | Q34271907 |
| | Acute pain management for patients receiving maintenance methadone or buprenorphine therapy | Q34485532 |
| | Fetal neurobehavioral effects of exposure to methadone or buprenorphine | Q34581552 |
| | Maternal methadone dose, placental methadone concentrations, and neonatal outcomes. | Q34626408 |
| | Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication | Q34721065 |
| | Fetal assessment before and after dosing with buprenorphine or methadone | Q34775584 |
| | The management of opioid dependence during pregnancy in rural and remote settings | Q34825515 |
| | Narcotic tapering in pregnancy using long-acting morphine: an 18-month prospective cohort study in northwestern Ontario | Q35077146 |
| | Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study | Q35220378 |
| | Perinatal substance use: a prospective evaluation of abstinence and relapse | Q35287442 |
| | UHPLC-MS/MS quantification of buprenorphine, norbuprenorphine, methadone, and glucuronide conjugates in umbilical cord plasma | Q35586688 |
| | Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study | Q35605499 |
| | Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome | Q35609885 |
| | Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome | Q38637999 |
| | Comorbidity of fetal alcohol spectrum disorder: a systematic review and meta-analysis | Q38699997 |
| | Breastfeeding among Mothers on Opioid Maintenance Treatment: A Literature Review | Q38800161 |
| | Buprenorphine Versus Methadone for Opioid Dependence in Pregnancy | Q38839159 |
| | The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy. | Q38853715 |
| | Impact of fetal alcohol exposure on body systems: A systematic review | Q38864049 |
| | Neonatal abstinence syndrome: Historical perspective, current focus, future directions | Q38978809 |
| | Opioid use disorder during pregnancy in Tennessee: expediency vs. science | Q38983591 |
| | Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy | Q39337207 |
| | Psychometric assessment of the Neonatal Abstinence Scoring System and the MOTHER NAS Scale | Q39692018 |
| | Detoxification from opiate drugs during pregnancy | Q39903531 |
| | Measurement of neonatal abstinence syndrome: Evaluation of short forms | Q39974449 |
| | Transfer of Methamphetamine (MA) into Breast Milk and Urine of Postpartum Women who Smoked MA Tablets during Pregnancy: Implications for Initiation of Breastfeeding. | Q40447619 |
| | Visual evoked potential latencies of three-year-old children prenatally exposed to buprenorphine or methadone compared with non-opioid exposed children: The results of a longitudinal study. | Q40472625 |
| | Development, Implementation, and Evaluation of a Pilot Parenting Educational Intervention in a Pregnancy Buprenorphine Clinic | Q40707553 |
| | Factors associated with buprenorphine versus methadone use in pregnancy | Q40777859 |
| | Prenatally buprenorphine-exposed children: health to 3 years of age. | Q40908237 |
| | Long-term opioid therapy: assessment of consequences and risks | Q40990139 |
| | Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial | Q35626714 |
| | Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process | Q35752218 |
| | Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes | Q35783426 |
| | Computer-Delivered Screening and Brief Intervention for Alcohol Use in Pregnancy: A Pilot Randomized Trial. | Q35815814 |
| | Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review | Q35863900 |
| | Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012 | Q35904559 |
| | Challenges that opioid-dependent women present to the obstetric anaesthetist. | Q36021790 |
| | Caring for pregnant opioid abusers in Vermont: A potential model for non-urban areas | Q36118052 |
| | Birth and Neonatal Outcomes Following Opioid Use in Pregnancy: A Danish Population-Based Study | Q36142245 |
| | American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. | Q36160536 |
| | A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations | Q36276101 |
| | Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study | Q36327652 |
| | The effect of prenatal alcohol co-exposure on neonatal abstinence syndrome in infants born to mothers in opioid maintenance treatment | Q36373210 |
| | Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers | Q36494953 |
| | Pharmacologic evidence to support clinical decision making for peripartum methadone treatment | Q36511123 |
| | Prescription Opioids in Pregnancy and Birth Outcomes: A Review of the Literature | Q36698128 |
| | Screening and evaluation of hepatitis C virus infection in pregnant women on opioid maintenance therapy: A retrospective cohort study | Q36785500 |
| | Prenatal, Perinatal and Neonatal Risk Factors for Intellectual Disability: A Systemic Review and Meta-Analysis. | Q36833247 |
| | Improving Care for Neonatal Abstinence Syndrome | Q36838250 |
| | Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes | Q36961530 |
| | Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone | Q37204964 |
| | Methadone maintenance and long-term lactation | Q37210284 |
| | The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations | Q37221649 |
| | The opioid-exposed newborn: assessment and pharmacologic management | Q37310917 |
| | Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial | Q37353540 |
| | Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome | Q37429615 |
| | Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes | Q37467788 |
| | An Evaluation of Rooming-in Among Substance-exposed Newborns in British Columbia | Q37807096 |
| | Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers | Q38152182 |
| | Prematurity reduces the severity and need for treatment of neonatal abstinence syndrome. | Q38331874 |
| | Maternal use of methadone and risk of sudden neonatal death. | Q38502801 |
| | Maternal and neonatal hair and breast milk in the assessment of perinatal exposure to drugs of abuse | Q38516618 |
| | Foetal programming and cortisol secretion in early childhood: A meta-analysis of different programming variables | Q38553936 |
| | Relational Care for Perinatal Substance Use: A Systematic Review | Q38570955 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | opioid | Q427523 |
| | opioid replacement therapy | Q652676 |
| | parenting | Q1217379 |
| | perinatal care | Q3411951 |
| | neonatal abstinence syndrome | Q6993502 |
| | opioid use disorder | Q1639178 |
| | complications of pregnancy | Q2916477 |
| | perinatal disease | Q18968218 |
| | opioid-related disorders | Q67085655 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 178-190 | |
| P577 | publication date | 2017-04-13 | |
| P1433 | published in | Journal of Addiction Medicine | Q15752435 |
| P1476 | title | Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children: Literature Review to Support National Guidance | |
| P478 | volume | 11 | |